Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Agios Pharmaceuticals, Inc. (AGIO)

31.52   2.13 (7.25%) 12-02 16:00
Open: 29.09 Pre. Close: 29.39
High: 31.675 Low: 28.8387
Volume: 443,104 Market Cap: 1,732(M)

Technical analysis

as of: 2022-12-02 4:20:44 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 36.99     One year: 43.21
Support: Support1: 27.37    Support2: 24.7
Resistance: Resistance1: 31.67    Resistance2: 36.99
Pivot: 28.95
Moving Average: MA(5): 29.71     MA(20): 28.48
MA(100): 27.52     MA(250): 27.23
MACD: MACD(12,26): 0.5     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 89.9     %D(3): 84.2
RSI: RSI(14): 63.4
52-week: High: 36.08  Low: 16.75
Average Vol(K): 3-Month: 556 (K)  10-Days: 346 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AGIO ] has closed It is unclear right now based on current values. 44.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 31.7 - 31.85 31.85 - 31.99
Low: 28.48 - 28.64 28.64 - 28.79
Close: 31.24 - 31.51 31.51 - 31.76

Company Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 02 Dec 2022
Rigel Pharma scores FDA approval for leukemia, kicking off showdown with Servier in IDH1 - Endpoints News

Fri, 02 Dec 2022
Asia-Pacific exerts pull on Mediterranean bitumen - Argus Media

Wed, 30 Nov 2022
The 25 best women's scarves to wrap up in winter 2022 - New York Post

Tue, 29 Nov 2022
Agios Andreas Of Patras, Largest Church In Greece - GreekCityTimes.com

Mon, 28 Nov 2022
Outdoor Furniture and Grill Market: Revenue Growth to Stoke Up in Next Couple of Years, Keyplayers Profile Outlook and Forecast Till 2028: Agio International Co. Inc., Homecrest Outdoor Living LLC, Brown Jordan Int Inc. - Digital Journal

Fri, 25 Nov 2022
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 55 (M)
% Held by Insiders 5.117e+007 (%)
% Held by Institutions 1.2 (%)
Shares Short 5,570 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.8575e+008
EPS Est Next Qtl -1.83
EPS Est This Year -7.08
EPS Est Next Year -7.37
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 974.8
Return on Equity (ttm) -18.2
Qtrly Rev. Growth 9.93e+006
Gross Profit (p.s.) 0
Sales Per Share -30.32
EBITDA (p.s.) 0
Qtrly Earnings Growth -6.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -327 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -1.04
Price to Cash Flow 1.63

Stock Dividends

Dividend 0
Forward Dividend 6.38e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.